Braided scaffolds

• US 10,004,834 B2
• Filed: 09/12/2014
• Issued: 06/26/2018
• Est. Priority Date: 09/13/2013
• Status: Expired due to Fees

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Hossainy, Syed Faiyaz Ahmed, Papp, John E., Harrington, Joel
• Primary Examiner(s): SCHILLINGER, ANN M
• Application Number:
  US14/484,943
• Publication Number:
  US 20150081000A1
• Time in Patent Office: 1,383 Days
• CPC Class Codes: A61F 2/88 the wire-like elements formed as helical or spiral coils forming a net-like or mesh-like structure A61F2/90
• CPC Class Codes: A61F 2/90 characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2/9517 handle assemblies therefor
• CPC Class Codes: A61F 2/966 with relative longitudinal movement between outer sleeve and prosthesis, e.g. using a push rod
• CPC Class Codes: A61F 2002/826 more than one stent being applied sequentially
• CPC Class Codes: A61F 2250/0018 differing in elasticity, stiffness or compressibility
• CPC Class Codes: A61F 2250/0031 made from both resorbable and non-resorbable prosthetic parts, e.g. adjacent parts
• CPC Class Codes: A61F 2250/0039 differing in diameter
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 31/128 containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

A braided polymeric scaffold, made at least in part from a bioresorbable material is deployed on a catheter that uses a push-pull mechanism to deploy the scaffold. A drug coating is disposed on the scaffold. A plurality of scaffold segments on a catheter is also disclosed.

Claims

1. A self-expanding stent for treating a peripheral vessel, comprising:

a segmented braided scaffold including a plurality of braided scaffold segments configured to be deployed end to end in a vessel, and

at least three of the braided scaffold segments are hybrid segments, each of which comprising non-degradable filaments and degradable filaments woven to form a tubular configuration,

wherein upon deployment of the scaffold from a collapsed state to a deployed state in a body cavity, the degradable filaments degrade and a radial strength or stiffness of the hybrid segments decreases with time,

wherein when the degradable filaments are completely degraded, each hybrid segment comprises a residual stiffness provided by the non-degradable filaments, and

wherein a hybrid proximal end segment a hybrid distal end segment of the scaffold have a higher radial strength or stiffness at deployment than a middle hybrid segment thereof, while having the same residual radial strength or stiffness as the middle hybrid segment, and wherein a first degradable polymer filament of the proximal and distal hybrid end segments has a higher degradation rate than a second degradable polymer filament of the middle hybrid segment so that a rate of decrease to the residual strength or stiffness is faster for the proximal and distal hybrid end segments than the middle hybrid segment.

2. The stent of claim 1, wherein the non-degradable filaments are nitinol.

3. The stent of claim 1, wherein the degradable filaments comprise a polymer selected from the group consisting of poly(L-lactide), poly(L-lactide-co-glycolide), poly(DL-lactide), and polyglycolide.

4. The stent of claim 1, wherein the degradable filaments comprise a bioabsorbable polymer.

5. The stent of claim 1, wherein the radial strength or stiffness of at least one of the hybrid end segments decreases by no greater than 60% during the first 3 months after deployment.

6. The stent of claim 1, wherein the radial strength or stiffness of at least one of the proximal and distal hybrid end segments decreases by at least about 50% during the first 3 months after deployment.

7. The stent of claim 1, wherein the stiffness of at least one of the proximal and distal hybrid end segments decreases to 40 to 60% of a stiffness at deployment during the first 3 months after deployment.

8. The stent of claim 1, wherein the stiffness of at least one of the proximal and distal hybrid end segments decreases to a residual stiffness that is less by 40% to 60% of a deployed stiffness, by at least 3 months after deployment.

9. The stent of claim 1, wherein a combined length of the distal and proximal hybrid end segments are 10% to 30% of a total length of the scaffold.

10. The stent of claim 1, wherein one of the hybrid proximal end segment and hybrid distal end segment comprises a metal filament having a cross sectional area (Am), and a degradable filament having a cross-sectional area (Ap), wherein the ratio Ap/Am is 2 to 4.

11. The stent of claim 1, wherein one of the hybrid proximal end segment and hybrid distal end segment comprises a number of metal filaments (Nm) and a number of polymer filaments (Np), wherein the ratio Np/Nm is 2 to 10.